Abstract
PURPOSE OF REVIEW: To determine whether alpha-blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate cancer risk. RECENT FINDINGS: Alpha-blockers have been associated with a reduced risk of prostate cancer aggressiveness in some observational studies and an increased risk in other studies. However, this relationship is complex as different alpha-blockers have divergent effects in laboratory studies and there are many confounders in daily practice such as differential screening practices. SUMMARY: Both benign prostatic hyperplasia and prostate cancer are common conditions in the aging male population, such that an interaction between alpha-blockers and prostate cancer risk is clinically relevant. Prospective evidence is necessary to establish a definitive link.
Original language | English (US) |
---|---|
Pages (from-to) | 2-4 |
Number of pages | 3 |
Journal | Current opinion in urology |
Volume | 23 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Keywords
- BPH
- alpha-blockers
- prognosis
- prostate cancer
- risk
ASJC Scopus subject areas
- Urology